Article Details
Retrieved on: 2021-07-16 05:26:15
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Celltrion's Monoclonal Antibody Treatment for COVID-19, regdanvimab (CT-P59), Demonstrates Strong Neutralising Activity Against Delta Variant.
Article found on: pipelinereview.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here